| Name | Title | Contact Details |
|---|
McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 21 Formula 1 world championships, 189 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt. McLaren Racing competes across six racing series. The team competes in the FIA Formula 1 World Championship with McLaren F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato OWard, Alexander Rossi and Nolan Siegel, the ABB FIA Formula E World Championship with NEOM McLaren Formula E Team drivers Sam Bird and Taylor Barnard, the Extreme E Championship with NEOM McLaren Extreme E Team drivers Cristina Gutiérrez and Mattias Ekström, and F1 Academy with ART Grand Prix and Driver Development programme member Bianca Bustamante. The team also competes in the F1 Sim Racing Championship as McLaren Shadow, having won the 2022 Constructors and Drivers Championships. McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.
PetVet Dx is a therapeutic management company focusing on delivering affordable, accurate, and rapid diagnostics with cutting-edge molecular technology and pharmaceuticals for veterinarians, farmers, and pet owners.
Arminco Inc. is the premier provider of dental design, construction, project management, and equipment sales & service. Projects are overseen by a full-service, in-house team of financial experts, designers, architects, contractors and equipment specialists. Projects include pediatric and orthodontics, surgical and other medical offices, veterinary practices as well as restaurants, churches, nail boutiques and other high end establishments. Founded in 1996, Arminco Inc. has grown from a small family business to a 50+ employee, multi-million dollar company operating throughout the US.
Price Forbes is an independent insurance broker established in 1893 and headquartered in London. As part of Ardonagh Specialty, it is recognized as a leading broker in the London market. The company has a global presence, with offices worldwide, and specializes in wholesale insurance broking, focusing on complex risk management solutions for large multinational companies. The services offered by Price Forbes include specialist insurance broking, risk management, and reinsurance solutions through its division, Price Forbes Re. This division provides tailored reinsurance broking, capital solutions, and strategic advisory services, utilizing analytics to meet client needs. Price Forbes also has a strong presence in Africa, with operations in South Africa and partnerships across sub-Saharan Africa. In addition to its business activities, Price Forbes is committed to community involvement through the Ardonagh Community Trust, supporting charitable initiatives and contributing over £1.5 million to various causes.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.